INNOVATE Corp. Third Quarter 2026 Earnings Conference Call - INNOVATE CORP

Explicit Guidance:

• No formal numerical guidance (revenue, earnings, margins, or full-year financial metrics) was provided for future periods.

Business-Segment Outlook:

• Infrastructure (DBM Global): Business exited Innovate ownership on October 5, 2026; future performance is not consolidated but retains value via Innovate's ownership interest in IES Holdings (the acquirer). DBM Global enters its next chapter with a "substantial backlog" and a "healthy pipeline" extending into 2027 and 2028.
• Life Sciences (MetaBeacon):
  • US/Global Commercialization: Targeting broader adoption of the TGFR system in kidney transplant donors, heart failure, and oncology over the next six to 12 months.
  • New Product Launch: Validation studies for a third-generation wireless TGFR sensor (with FDA investigational device exemption approval) are scheduled to commence in the United States.
  • Pharmaceutical Partnerships: Initial usage of transdermal GFR technology by Big Pharma in clinical trials is anticipated to begin in 2027.
  • International Expansion (China): Orders for 600 TGFR monitors are secured; shipments are planned from Q4 2026 through Q2 2027.
• Life Sciences (R2):
  • Revenue Pipeline: Exited Q3 2026 with 116 systems in inventory/carried forward, representing approximately $1.9 million in future revenue.
  • Capacity Expansion: Production of "Glacial FX" at Electronic Instrument and Technology (EIT) is underway; 30 units delivered, ~60 units in production, with deliveries anticipated by November 30, 2026.
  • Strategy: Focused on converting strong underlying demand into revenue and expanding international presence.
• Spectrum:
  • Ownership Stake: Innovate retains a 25% ownership interest (with an option to acquire up to an additional 15% to reach 40%) following the sale of controlling interest to ConnexCorp.
  • Business Activity: ConnexCorp will continue expanding utility of spectrum assets and pursuing additional station acquisitions; the business has 287 operating stations and is positioned for a potential second broadcast auction.

Market and Competitive Outlook:

• Infrastructure Demand: Expectations for continued investment in infrastructure supporting computing, artificial intelligence (AI), advanced manufacturing, semiconductor production, energy systems, and digital connectivity.
• Backlog Environment: DBM Global demonstrated ability to replenish backlog at high levels while executing on existing volume, indicating strong underlying demand and customer relationships.

Macro / Industry Outlook:

• Regulatory/Pricing: Management expects ongoing engagement with the Centers for Medicare and Medicaid Services (CMS) and private payers to secure additional reimbursement coding critical for MetaBeacon's TGFR system adoption.
• M&A/Strategic Value: Anticipated milestone payments from the 2018 Benevir sale (via Pantensend) total up to $900 million aggregate, with $500 million potentially due to Innovate. These are tied to specific regulatory approvals and net sales thresholds for future commercialization of Genoval (knee replacements).

Strategic Initiatives:

• Portfolio Simplification: Completion of the sale of DBM Global (October 5, 2026) and controlling interest in Spectrum to sharpen focus on remaining assets.
• Capital Allocation: Proceeds from the DBM Global sale ($413 million received) were used to repay the corporate credit line and redeem $325 million of senior secured notes, reducing total principal indebtedness to $238.3 million.
• Future Financial Strategy: Expect to further reduce indebtedness as remaining assets are monetized; management commits to a "disciplined approach" and evaluating opportunities to unlock value.

Risks and Headwinds to Outlook:

• Commercialization Timelines: New technology conversion and adoption cycles (e.g., MetaBeacon) can take six to 12 months, introducing uncertainty regarding revenue timing.
• Reimbursement Dependency: Broader adoption of MetaBeacon's TGFR system is contingent on success with reimbursement coding from CMS and private payers.
• Operational/Market Volatility: Potential fluctuations in material costs affecting margins and delays in clinical trial initiation or regulatory approvals.
• Market Uncertainty: Success of "second broadcast auction" for the Spectrum subsidiary remains contingent on regulatory action ("should it come to pass").

Management Tone on the Future:

• Confidence: Expressed as "encouraged" by portfolio momentum and "excited" about future opportunities via IES Holdings interest and MetaBeacon's growth.
• Strategic Shift: Transitioning from a diversified holding company to a focused portfolio on MetaBeacon and R2, emphasizing "long-term value" and "financial discipline."
• Hedges: Cautionary language regarding the "six to 12 months" timeline for technology adoption and the conditional nature of future regulatory approvals and auction opportunities.

Miscellaneous:

• Financial Results Context: Q3 2026 revenue was $495.5 million (including $490.6M from DBM Global prior to sale); adjusted EBITDA was $40.5 million.
• Debt Status: Total indebtedness reduced from $583.3 million (end of 2025) to $238.3 million post-transaction.
• Asset Sales Proceeds: $413 million cash received from DBM Global sale; $325 million used for debt redemption.